Learn what biomarker testing is and why it matters before starting treatment in lung cancer.

In Part 1 of the Young Lung Cancer Initiative Biomarker Education Series, Dr. Ben Creelan and Dr. Jhanelle Gray from Moffitt Cancer Center break down the basics of biomarker testing in plain language.

This episode is sponsored by Nuvation Bio.

Learn about the future of the ROS1 treatment landscape and the reality of long-term survivorship with thoracic oncologist Dr. Estelamari Rodriguez.

This episode is sponsored by Nuvation Bio.

In Part 3 of the Young Lung Cancer Initiative ROS1 Biomarker Series, we conclude our deep dive into life with ROS1 with Dr. Estelamari Rodriguez, a thoracic oncologist at Sylvester Comprehensive Cancer Center at the University of Miami.

This educational video explores what is on the horizon for ROS1 positive lung cancer, focusing on the research pipeline and next-generation clinical trials.

The conversation shifts to the personal side of the journey, offering insights on how to balance rigorous treatment with a full life.

Learn about the ROS1 treatment landscape and managing treatment side effects with thoracic oncologist Dr. Estelamari Rodriguez.

This episode is sponsored by Nuvation Bio.

In Part 2 of the Young Lung Cancer Initiative ROS1 Biomarker Series, we dive into the "meat and potatoes" of treatment with Dr. Estelamari Rodriguez, a thoracic oncologist at Sylvester Comprehensive Cancer Center at the University of Miami.

This educational video explores the current standard of care for ROS1 positive lung cancer, from early-stage management to metastatic disease. Dr. Rodriguez discusses the evolution of targeted therapies—including next-generation tyrosine kinase inhibitors (TKIs) and explains how these newer drugs are moving the needle for patients with brain metastases.

The conversation provides practical suggestions on navigating common ROS1 TKI side effects, such as dizziness (CNS effects), taste changes, and GI issues. Dr. Rodriguez emphasizes why open communication with your care team about dose adjustments and "drug holds" is vital for maintaining a high quality of life while staying on treatment longer.

Coming Up Next: In Part 3, we will conclude the series by discussing the reality of "Living with ROS1," including progression, long-term survivorship, and the future of research.